---
document_datetime: 2026-02-16 09:22:42
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/enspryng-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: enspryng-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7005635
conversion_datetime: 2026-02-18 17:50:38.516346
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Enspryng

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.b.5 Change to in-process tests or limits | 06/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000322896                     | applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted                                                                                                                                                                                                                                                                                                                                                                          |            |            |                                  |                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000293585   | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Enspryng in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity. | 11/12/2025 | 10/02/2026 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Enspryng in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                            |
| Variation type II / EMA/VR/0000249656 | This was an application for a group of variations. B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control                                                                               | 25/04/2025 | 28/08/2025 | Annex II and PL                  | Annex II has been updated as follows: To add the name and address of the manufacturer of the biological active substance: WuXi Biologics Co., Ltd., 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu 214092 China In addition, the list of local representatives in the package leaflet is being revised. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                            | no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of   |             |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| PSUR / EMA/PSUR/0000296560 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Maintenance |